NantKwest and ImmunityBio to initiate a phase 2 study of immunotherapy for metastatic pancreatic cancer

This article was originally published here

Four metastatic pancreatic cancer patients have been treated with PD-L1 t-haNK and N-803 under single patient INDs, with two patients on treatment for an evaluable period. One patient reported

The post NantKwest and ImmunityBio to initiate a phase 2 study of immunotherapy for metastatic pancreatic cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply